#None #Vienna #Ribbon Bio #MiroMine #Jay Therrien

Ribbon Bio Welcomes Jay Therrien as Chief Business Officer

In an exciting development for the cell-free DNA assembly industry, Ribbon Bio has announced that Jay Therrien will join its executive leadership team as Chief Business Officer. With over twenty years of extensive experience in the life sciences and genomics sectors, Therrien's arrival marks a significant milestone for Ribbon Bio as they seek to elevate their market presence and drive innovation in DNA synthesis.

Therrien brings a wealth of expertise, having served most recently as Chief Commercial Officer at Ultima Genomics. His previous leadership roles include positions at notable companies such as IDEX Health Science, RainDance Technologies, Life Technologies, and Illumina. His track record includes launching several transformative technologies like multiplex genotyping, digital PCR, and next-generation sequencing platforms, showcasing his ability to navigate and shape the rapidly evolving genomics landscape.

At Ribbon Bio, Therrien will spearhead the company's commercial strategy and growth initiatives as it aims to facilitate broader adoption of its innovative cell-free DNA solutions. A key focus of his efforts will be on the recently launched MiroMine™ kit, which provides laboratories with access to Ribbon Bio's advanced assembly algorithms and synthesis processes. This technology represents a significant leap forward in enabling researchers to interact with complex DNA constructs more efficiently and effectively.

Therrien expressed enthusiasm about his new role, stating, "After thoroughly examining Ribbon's cutting-edge technology, operational structure, and long-term market potential, it is evident that the company occupies a unique position to redefine the landscape of DNA synthesis. The shift from traditional cloning methods to more advanced solutions like ours is not just timely but necessary as the demand for sophisticated DNA molecules continues to escalate. Importantly, with the MiroMine kits, researchers do not need specialized lab equipment, thus streamlining the adoption process. We anticipate a swift embrace of this technology as labs can begin generating high-fidelity, cell-free DNA constructs independently."

Jodi Barrientos, CEO of Ribbon Bio, welcomed Therrien to the team, emphasizing the importance of his expertise as the company works towards scaling operations and advancing its vision for the future of DNA synthesis. She remarked, "We are thrilled to bring Jay onto our executive team. His vast commercial experience and proven success will be invaluable as we continue to push boundaries in our industry."

About Ribbon Bio

Ribbon Bio is positioned at the forefront of innovation in cell-free DNA assembly, aiming to transform the accessibility and quality of high-fidelity DNA molecules. By developing DNA outside of bacterial-mediated processes, Ribbon Bio circumvents many traditional limitations associated with plasmid-based DNA production. The company’s methodologies promise purer DNA free from endotoxin contamination, accelerated production timelines, and enhanced reliability at scale.

This novel cell-free DNA assembly approach enables researchers to acquire DNA molecules of unprecedented length, structure, and complexity, eliminating historical challenges that have constrained scientific innovation. With proprietary algorithms and extensive manufacturing capabilities, Ribbon Bio is democratizing synthetic DNA usage, making it a foundational tool for pioneering advancements in science and health. As the company continues to develop and expand its product offerings, Ribbon Bio is committed to supporting the growth and evolution of numerous scientific domains.

To learn more about Ribbon Bio and its innovative solutions, visit www.ribbonbio.com.